Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA and BECOX) to determine if hypertension and proteinuria predict outcome in elderly patients with mCRC treated with bevacizumab. day 1 (BECOX study). The primary objective was to correlate hypertension and proteinuria with overall response rate (ORR), time to progression (TTP) and overall survival (OS). Secondary objectives included identification of risk factors associated with the development of hypertension and proteinuria and determining whether development of hypertension or proteinuria in the first 2 cycles was related to ORR, diseas...
IF 7.191 (2017)International audienceBackgroundOlder patients have frailty characteristics that impa...
BACKGROUND: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastat...
Thesis (Master's)--University of Washington, 2012Background: The safety of bevacizumab in older met...
BACKGROUND:Studies suggest a relationship between hypertension and outcome in bevacizumab-treated pa...
Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated pa...
Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated...
Background: Retrospective series suggest that bevacizumab-induced hypertension (HTN) is a prognostic...
Abstract BACKGROUND: Arterial hypertension occurring during antiangiogenic therapy has been correla...
Bevacizumab neutralizes a key stimulation factor in tumour angiogenesis - vascular endothelial growt...
Purpose: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (Irinote...
PURPOSE: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (iri...
monoclonal antibody, in combination with regimens based on 5FU/LV (or capecitabine) ± irinotecan o...
Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastat...
Nephrotic-range proteinuria, which denotes structural damage to the glomerular filtration barrier, o...
<p><b>Background:</b> Hypertension is a common early adverse event of anti-angiogenic treatment of c...
IF 7.191 (2017)International audienceBackgroundOlder patients have frailty characteristics that impa...
BACKGROUND: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastat...
Thesis (Master's)--University of Washington, 2012Background: The safety of bevacizumab in older met...
BACKGROUND:Studies suggest a relationship between hypertension and outcome in bevacizumab-treated pa...
Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated pa...
Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated...
Background: Retrospective series suggest that bevacizumab-induced hypertension (HTN) is a prognostic...
Abstract BACKGROUND: Arterial hypertension occurring during antiangiogenic therapy has been correla...
Bevacizumab neutralizes a key stimulation factor in tumour angiogenesis - vascular endothelial growt...
Purpose: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (Irinote...
PURPOSE: Patients with metastatic colorectal cancer (mCRC) receiving all three active drugs (iri...
monoclonal antibody, in combination with regimens based on 5FU/LV (or capecitabine) ± irinotecan o...
Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastat...
Nephrotic-range proteinuria, which denotes structural damage to the glomerular filtration barrier, o...
<p><b>Background:</b> Hypertension is a common early adverse event of anti-angiogenic treatment of c...
IF 7.191 (2017)International audienceBackgroundOlder patients have frailty characteristics that impa...
BACKGROUND: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastat...
Thesis (Master's)--University of Washington, 2012Background: The safety of bevacizumab in older met...